Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Claims of “Ineffective” Generics Might Be Due to Placebo Effect in Some Cases: Mr Yoshida of HIB
June 25, 2012
- MHLW to Strengthen Focus on Dementia with Budget Request for FY2013
June 22, 2012
- MHLW to Draft New Guidelines on Pharmacotherapy for Dementia
June 22, 2012
- Nichi-Iko No. 1 in Terms of the Number of Generics Listed in June; Pfizer at 4th
June 22, 2012
- 60% Rule Applied for 3 APIs in June’s Generic Listing
June 22, 2012
- Access System for Unapproved Drugs to Be Submitted at Next Ordinary Diet Session “at the Latest”: Mr Kawai of DPJ
June 21, 2012
- MHLW Calls for OTC Switch for Hyaluronate Sodium
June 21, 2012
- Establishment of Third-Party Organization “Historical”: DPJ Member Kawai
June 20, 2012
- PMDA’s Science Committee Holds 1st Meeting; Will Work to Improve Review Quality through Exchanges with Researchers
June 20, 2012
- MHLW Committee Compiles Discussion Points on System for Public Release of Drug Damage Documents
June 20, 2012
- MHLW Withdraws Orphan Drug Designation for Somatropin
June 18, 2012
- MHLW Designates 5 Products, Including CLL Treatment, as Orphan Drugs
June 18, 2012
- DPJ Approves Draft Bill to Establish 3rd-Party Organization; Will Seek Discussions with Opposition
June 18, 2012
- Developed or Developing Countries: Which Side Is Right on Humanitarian Aid?
June 18, 2012
- MHLW Selects Kitasato Univ. Hospital, FBRI as Base for Japan-Led Global Clinical Research
June 15, 2012
- Mr Umemura of DPJ Proposes Obligatory Use of Generics for Welfare Recipients
June 15, 2012
- MHLW Study Group Might Postpone Concrete Conclusion on Relief System for Victims of Health Damage Due to Anticancer Drugs
June 13, 2012
- Ryukaikon’s Working Team Prepares to Start Operations by End of June; Beginning with Exchange of Opinions between JPWA, NPhA
June 13, 2012
- With Consumption Tax Hike in 2015, “Focus on Whether to Conduct Market Price Survey”: EAD Director Kamata
June 12, 2012
- PAFSC Committee Gives Green Light to OTC Switching of Hyaluronate Sodium
June 11, 2012
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…